Sean Smith - Mar 2, 2022 Form 3 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
Principal Accounting Officer
Signature
/s/ Sean M. Smith
Stock symbol
NLTX
Transactions as of
Mar 2, 2022
Transactions value $
$0
Form type
3
Date filed
3/3/2022, 03:38 PM
Next filing
Aug 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NLTX Common Stock 3.43K Mar 2, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NLTX Employee Stock Option (Right to buy) Mar 2, 2022 Common Stock 26K $2.71 Direct F1
holding NLTX Employee Stock Option (Right to buy) Mar 2, 2022 Common Stock 24K $6.80 Direct F2
holding NLTX Employee Stock Option (Right to buy) Mar 2, 2022 Common Stock 15K $12.00 Direct F3
holding NLTX Restricted Stock Units Mar 2, 2022 Common Stock 10K Direct F4, F5, F6
holding NLTX Restricted Stock Units Mar 2, 2022 Common Stock 25K Direct F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option vested on October 21, 2020, and 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 1/4 of the shares subject to the option will vest on August 3, 2022, and then 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3 1/4 of the shares subject to the option vested on August 10, 2021, and 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4 The restricted stock units ("RSUs") will vest as to 1/2 of the total number of shares underlying the award on each of August 10, 2022 and August 10, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F5 RSUs do not expire; they either vest or are canceled prior to the vesting date.
F6 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F7 The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.